SLC STATES and the EBOLA VIRUS an ISSUE ALERT from the SLC Legislative Conference
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Eradicating Ebola: Lessons Learned and Medical Advancements Hearing
ERADICATING EBOLA: LESSONS LEARNED AND MEDICAL ADVANCEMENTS HEARING BEFORE THE SUBCOMMITTEE ON AFRICA, GLOBAL HEALTH, GLOBAL HUMAN RIGHTS, AND INTERNATIONAL ORGANIZATIONS OF THE COMMITTEE ON FOREIGN AFFAIRS HOUSE OF REPRESENTATIVES ONE HUNDRED SIXTEENTH CONGRESS FIRST SESSION JUNE 4, 2019 Serial No. 116–44 Printed for the use of the Committee on Foreign Affairs ( Available: http://www.foreignaffairs.house.gov/, http://docs.house.gov, or http://www.govinfo.gov U.S. GOVERNMENT PUBLISHING OFFICE 36–558PDF WASHINGTON : 2019 COMMITTEE ON FOREIGN AFFAIRS ELIOT L. ENGEL, New York, Chairman BRAD SHERMAN, California MICHAEL T. MCCAUL, Texas, Ranking GREGORY W. MEEKS, New York Member ALBIO SIRES, New Jersey CHRISTOPHER H. SMITH, New Jersey GERALD E. CONNOLLY, Virginia STEVE CHABOT, Ohio THEODORE E. DEUTCH, Florida JOE WILSON, South Carolina KAREN BASS, California SCOTT PERRY, Pennsylvania WILLIAM KEATING, Massachusetts TED S. YOHO, Florida DAVID CICILLINE, Rhode Island ADAM KINZINGER, Illinois AMI BERA, California LEE ZELDIN, New York JOAQUIN CASTRO, Texas JIM SENSENBRENNER, Wisconsin DINA TITUS, Nevada ANN WAGNER, Missouri ADRIANO ESPAILLAT, New York BRIAN MAST, Florida TED LIEU, California FRANCIS ROONEY, Florida SUSAN WILD, Pennsylvania BRIAN FITZPATRICK, Pennsylvania DEAN PHILLIPS, Minnesota JOHN CURTIS, Utah ILHAN OMAR, Minnesota KEN BUCK, Colorado COLIN ALLRED, Texas RON WRIGHT, Texas ANDY LEVIN, Michigan GUY RESCHENTHALER, Pennsylvania ABIGAIL SPANBERGER, Virginia TIM BURCHETT, Tennessee CHRISSY HOULAHAN, Pennsylvania GREG PENCE, Indiana -
Fighting Ebola: a Strategy for Action
FIGHTING EBOLA: A STRATEGY FOR ACTION Vera Songwe, Nonresident Senior Fellow, Africa Growth Initiative THE PRIORITY Despite these overwhelming numbers, prog- ress is being made in the fight against these African populations continue to suffer under diseases. For example, malaria mortality rates in the heavy burden of disease despite overall sus- children in Africa were reduced by an estimat- tained increases in income levels over the last ed 54 percent between 2002 and 2012. Since decade. Three major diseases are among those 2000, there has been a 49 percent reduction responsible for health crises: malaria, HIV/AIDS in the overall malaria mortality rates in Africa. and tuberculosis, and, in 2014, the Ebola virus For HIV, by the end of 2012, about 68 percent emerged as a fourth virus with pandemic po- of eligible persons were receiving antiretroviral tential. treatment, an increase of more than 90 percent since 2009 (UNAIDS 2013). In 2012, for example, 80 percent of the estimat- ed 207 million malaria cases worldwide were However, 2014 in West Africa will be remem- found in Africa, and 90 percent of the estimat- bered not for progress made in combatting in- ed 627,000 global malaria deaths occurred in fectious diseases but as the year the Ebola virus Africa. On average, malaria kills a child every crippled three countries on the continent and minute, of which 90 percent occur among Afri- inflicted economic damage to many others. can children. Malaria-related anemia is estimat- The 20th Ebola outbreak globally has captured ed to cause thousands of deaths a year—and the attention of the world like none of the oth- for countries with endemic malaria, it is estimat- ers that have preceded it and like no other dis- ed that there is a 1.3 percentage point loss in ease has in recent history. -
Ebola Viral Disease Outbreak-2014: Implications and Pitfalls
View metadata, citation and similar papers at core.ac.uk brought to you by CORE OPINION ARTICLE published: 01 Decemberprovided by 2014 Frontiers - Publisher Connector PUBLIC HEALTH doi: 10.3389/fpubh.2014.00263 Ebola viral disease outbreak-2014: implications and pitfalls Mahip Acharya* Independent Researcher, Kathmandu, Nepal *Correspondence: [email protected] Edited by: Philip Arthur Mackowiak, University of Maryland School of Medicine, USA Reviewed by: Mohammad Mohseni Sajadi, Institute of Human Virology at the University of Maryland School of Medicine, USA Keywords: Ebola virus outbreak, zoonosis, pharmaceutical industries, ethics in drug approval, global health West Africa – consisting of countries hemorrhagic fever outbreak in southern numerous strains of a single virus species such as Guinea, Liberia, Sierra Leone, and Sudan and northern Zaire (5). Ebola viral and their continued mutation – as is the Nigeria – is the westernmost region of the disease, a zoonotic disease, has since been case with the current Ebola infection (8)– African continent. Afflicted by widespread observed intermittently in different regions often stymies the research for anti-viral poverty and political instability,WestAfrica of Central Africa (6), but none of those drugs. This is similar to the case with is one of the poorest regions in the world – has wreaked damage as monumental as the antibiotics, where bacterial resistance is a Liberia, Sierra Leone, and Guinea are ongoing outbreak. chief concern (9). Bacterial and viral dis- respectively ranked 174, 177, and178 out The current Ebola viral disease outbreak eases benefit from the ever-evolving genetic of 187 countries on the United Nations is turning out to be an insidious threat makeup of their agents, which are capable Development Program Human Develop- to the public health of West Africa – and of rapidly rendering a treatment ineffec- ment Index (1). -
Tech at the Service of the Fight Against Epidemics in West Africa
Study report for the Pierre Fabre Foundation’s Global South eHealth Observatory Tech at the service of the fight against epidemics in West Africa Born experimentally with Ebola, the use of technology to fight epidemics for a faster, more efficient and social management of the crisis in West Africa, has now reached its full potential with Covid-19, benefitting the health of African populations. Julie LANCKRIET Under the Direction of Samir ABDELKRIM StartupBRICS 1 CONTENTS I. DATAS AGAINST Ebola, OR TECH TO SERVE CRISIS MANAGEMENT ..................................................... 4 A. In an organic and incremental way, the Tech supports the fight against the virus. ......................... 4 1) INFORM AND RAISE AWARENESS ................................................................................................. 5 2) TRACE AND LOCATE ...................................................................................................................... 6 3) DIAGNOSE, COLLECT AND REPORT DATA ..................................................................................... 7 4) TO SUPPORT PEOPLE ECONOMICALLY THROUGH ELECTRONIC TRANSFERS, A PROMISING BUT STILL PREMATURE EXPERIMENT ......................................................................................................... 10 B. Case study: Ebola management in Nigeria, an example of an immediate and controlled response by the Tech. ............................................................................................................................................ -
Hand Hygiene Practices During and After Ebola Virus Disease Outbreak Pepple N* and Akpan E Salem University, Lokoja, Nigeria
ty & Gl afe ob S a l l a H e Pepple and Akpan, Med Saf Glob Health 2017, 6:2 c i a d l t e h M Medical Safety & Global Health DOI: 10.4172/2574-0407/1000137 ISSN: 2574-0407 Research Article Open Access Responses to Epidemic Prevention in Nigeria; Hand Hygiene Practices During and After Ebola Virus Disease Outbreak Pepple N* and Akpan E Salem University, Lokoja, Nigeria Abstract Most infections are thought to be transmitted by contact with an infected person’s body fluid, e.g., Ebola virus disease (EVD). Following the recent EVD outbreak in Nigeria, the essence of this study was to assess the responses to epidemic prevention in Nigeria by individuals and institutions; a comparative study of hand hygiene practices during and after EVD outbreak was carried out. The aim of this study was to indirectly assess the level of the nation’s preparedness to combating disease outbreak by assessing the attitude and practice of hand hygiene among the general population and institutions in Abuja – FCT, Nigeria, after the EVD outbreak and to investigate the presence of the necessary facilities and supplies required for hand hygiene in institutions (schools, banks, hospitals, hotels and NGOs working on healthcare). These institutions were observed to be complying with high hygiene and safety practices and had adequate prevention facilities during the EVD outbreak in Nigeria. A cross-sectional descriptive and observational study was conducted. Observation of the presence of safety facilities and utilization/compliance was conducted at the selected institutions. Staff attitudes and perceptions towards hand hygiene were assessed through self-administered questionnaire to management staff in 10 different institutions: 2 each of schools, hospitals, banks, hotels and health NGOs. -
Ebola Virus Disease October 2014 • $12.00 US
SPECIAL DIGITAL ISSUE: Ebola Virus Disease October 2014 • $12.00 US EBOLA VIRUS DISEASE A Primer for Infection Preventionists Ebola Virus Disease: A Primer for Infection Preventionists By Kelly M. Pyrek ccording to the Centers for Disease Control and Prevention (CDC), Ebola — previously known as AEbola hemorrhagic fever — is a rare and deadly disease caused by infection with one of the Ebola virus strains. Ebola can cause disease in humans and non- human primates. Ebola is caused by infection with a virus of the family Filoviridae, genus Ebolavirus. There Ebola, previously known are five identified Ebola virus species, four of which are known to cause disease in humans: Ebola virus as Ebola hemorrhagic (Zaire ebolavirus); Sudan virus (Sudan ebolavirus); fever, is a rare and Taï Forest virus (Taï Forest ebolavirus, formerly Côte d’Ivoire ebolavirus); and Bundibugyo virus (Bundibugyo deadly disease caused ebolavirus). The fifth, Reston virus (Reston ebolavirus), by infection with one of has caused disease in non-human primates, but not in humans. the Ebola virus strains. Ebola was first discovered in 1976 near the Ebola River in what is now the Democratic Republic of the Congo. Since then, outbreaks have appeared sporadically in Africa. The natural reservoir host of Ebola virus remains unknown; however, on the basis of evidence and the nature of similar viruses, researchers believe that the virus is animal-borne and that bats are the most likely reservoir. Four of the five virus strains occur in an animal host native to Africa. INFECTION CONTROL TODAY Ebola Virus Disease www.infectioncontroltoday.com 3 The Outbreak Situation at Home and Abroad: An Update As of Oct. -
Ebola Hemorrhagic Fever Ebola Virus Disease (EVD)
Infectious Disease Epidemiology Section Office of Public Health, Louisiana Dept. of Health & Hospitals 800-256-2748 (24 hr. number) www.infectiousdisease.dhh.louisiana.gov Ebola Hemorrhagic Fever Ebola Virus Disease (EVD) 12/01/2014 “The bottom line with Ebola is we know how to stop it: traditional public health. Find patients, isolate and care for them; find their contacts; educate people; and strictly follow infection control in hospitals. Do those things with meticulous care and Ebola goes away.” Tom Frieden, MD, MPH - Director of the Centers for Disease Control and Prevention This manual is based on the CDC recommendations. It is presented in a very concise format to provide infection preventionists and epidemiologists a single document grouping all information necessary to understand Ebola transmission, patient management and epidemic prevention. This manual is updated weekly. For the most recent information access the CDC website. The word Ebola is sometimes used as a synonym for Ebola Virus Disease. Table of Contents Ebola Hemorrhagic Fever....................................................................................................................... 1 1-Epidemiology ...................................................................................................................................... 6 1.1-The virus ...................................................................................................................................... 6 1.2-Incubation period is important .................................................................................................... -
Understanding Ebola: the 2014 Epidemic Jolie Kaner1,2 and Sarah Schaack2*
Kaner and Schaack Globalization and Health (2016) 12:53 DOI 10.1186/s12992-016-0194-4 REVIEW Open Access Understanding Ebola: the 2014 epidemic Jolie Kaner1,2 and Sarah Schaack2* Abstract Near the end of 2013, an outbreak of Zaire ebolavirus (EBOV) began in Guinea, subsequently spreading to neighboring Liberia and Sierra Leone. As this epidemic grew, important public health questions emerged about how and why this outbreak was so different from previous episodes. This review provides a synthetic synopsis of the 2014–15 outbreak, with the aim of understanding its unprecedented spread. We present a summary of the history of previous epidemics, describe the structure and genetics of the ebolavirus, and review our current understanding of viral vectors and the latest treatment practices. We conclude with an analysis of the public health challenges epidemic responders faced and some of the lessons that could be applied to future outbreaks of Ebola or other viruses. Keywords: Ebola, Ebolavirus, 2014 outbreak, Epidemic, Review Abbreviations: BEBOV, Bundibugyo ebolavirus;CIEBOV,Côte d’Ivoire ebolavirus;EBOV,Ebolavirus; EVD, Ebola virus disease or Ebola; Kb, Kilobase; MSF, Médecins Sans Frontières; REBOV, Reston ebolavirus; SEBOV, Sudan ebolavirus;WHO,World Health Organization; ZEBOV, Zaire ebolavirus Background NP (nucleoprotein), VP35 (polymerase cofactor), VP40 As of April 13th, 2016 there have been 28,652 total cases (matrix protein), GP (glycoprotein), VP30 (transcrip- of Ebola virus disease (EVD; or more generally Ebola) in tion activator), VP24 (secondary matrix protein), and the 2014–2015 West African epidemic [1]. Of these, RNA-dependent RNA polymerase [6]. There are currently 11,325 cases (40 %) were fatal [1]. -
Texas Ebola Patient Gets Experimental Drug (Update) 6 October 2014, by Kerry Sheridan
Texas Ebola patient gets experimental drug (Update) 6 October 2014, by Kerry Sheridan A Liberian man diagnosed with Ebola in Texas was fellow heads of state and government around the given an experimental drug for the first time, world to make sure that they are doing everything officials said Monday as the White House mulled that they can to join us in this effort." tougher airport screening at home and abroad. He said the United States is considering tougher Thomas Eric Duncan was given the investigational airport screening to ward against the spread of medication, brincidofovir, on Saturday, the day his cases by airline travelers. condition worsened from serious to critical, said Texas Health Presbyterian Hospital Dallas. "We're also going to be working on protocols to do additional passenger screening both at the source The medication is made by the North Carolina- and here in the United States," Obama told based pharmaceutical company Chimerix, and until reporters. now had never been tried in humans with Ebola, the company said. In Nebraska, a US photojournalist who tested positive for Ebola in Liberia arrived at a hospital However, it has been tested in about 1,000 people and was able to walk off the airplane that carried against adenovirus and cytomegalovirus. him. The drug "works by keeping viruses from creating "We are really happy that his symptoms are not additional copies of themselves," Chimerix said. extreme yet," Ashoka Mukpo's mother, Diana, told reporters, adding that he was feverish and Duncan is the first person to be diagnosed with nauseous. Ebola in the United States, and he is believed to have become infected while in Liberia. -
Ebola Fast Facts by CNN Library Updated 10:43 AM EDT, Fri October 3, 2014 CNN.Com
http://www.cnn.com/2014/04/11/health/ebola-fast-facts/ Ebola Fast Facts By CNN Library updated 10:43 AM EDT, Fri October 3, 2014 CNN.com (CNN) -- Here's some background information about Ebola, a virus with a high fatality rate that was first identified in Africa in 1976. Facts: Ebola hemorrhagic fever is a disease caused by one of five different Ebola viruses. Four of the strains can cause severe illness in humans and animals. The fifth, Reston virus, has caused illness in some animals, but not in humans. The first human outbreaks occurred in 1976, one in northern Zaire (now Democratic Republic of the Congo ) in Central Africa: and the other, in southern Sudan (now South Sudan). The virus is named after the Ebola River, where the virus was first recognized in 1976, according to the Centers for Disease Control and Prevention. Ebola is extremely infectious but not extremely contagious. It is infectious, because an infinitesimally small amount can cause illness. Laboratory experiments on nonhuman primates suggest that even a single virus may be enough to trigger a fatal infection. Instead, Ebola could be considered moderately contagious, because the virus is not transmitted through the air. The most contagious diseases, such as measles or influenza, virus particles are airborne. Humans can be infected by other humans if they come in contact with body fluids from an infected person or contaminated objects from infected persons. Humans can also be exposed to the virus, for example, by butchering infected animals. While the exact reservoir of Ebola viruses is still unknown, researchers believe the most likely natural hosts are fruit bats. -
West Africa Ebola Epidemic
Chapter Two: West Africa Ebola Epidemic Author’s Note: The analysis and comments regarding the communication efforts described in this case study are solely those of the authors; this analysis does not represent the official position of the FDA. This case was selected, because it is a highly relevant and recent example of the challenges of communicating about medical countermeasures (MCMs). The West Africa Ebola epidemic posed unique challenges in that the only available MCM options were still in development, requiring special messaging to address the relevant authorization and approval processes and uncertainty regarding the products’ safety and efficacy. This case study does not provide a comprehensive assessment of all communication efforts. The authors intend to use this case study as a means of highlighting communication challenges strictly within the context of this incident, not to evaluate the success or merit of individual investigational products or any changes made as a result of these events. Abstract In late 2013, an Ebola outbreak began in Guinea, quickly growing to become the largest Ebola epidemic on record. Widespread transmission occurred in Guinea, Liberia, and Sierra Leone with imported cases and limited transmission occurring in other countries, including the United States. The absence of approved medical countermeasures (MCMs) and a severely limited supply of investigational drugs—in early stages of development and with limited production capacity—compounded delays in the global response to the epidemic. Several -
Africa Update
ML Strategies Update David Leiter, [email protected] ML Strategies, LLC Georgette Spanjich, [email protected] 701 Pennsylvania Avenue, N.W. Sarah Mamula, [email protected] Washington, DC 20004 USA 202 296 3622 202 434 7400 fax FOLLOW US ON TWITTER: @MLStrategies www.mlstrategies.com OCTOBER 17, 2014 Africa Update Leading the News West Africa Ebola Outbreak On October 9th, while visiting Guinea, Director of Policy for the United Nations (U.N.) Development Programme (UNDP) Magdy Martinez-Soliman said urgent support is needed in Guinea to prevent an economic meltdown as a result of the Ebola crisis. Director Martinez-Soliman observed Ebola is now impacting every aspect of people’s lives, especially as it is limiting jobs and essential services, decreasing exports of fruits and vegetables, and significantly decreasing travel. While in Guinea, Director Martinez-Soliman and UNDP Deputy Director for Africa Ruby Sanhu-Rojon visited Ebola treatment centers and met with government agencies and other entities involved in stopping the spread of the virus. More information can be seen here. On October 9th, U.S. Agency for International Development (USAID) Administrator Rajiv Shah authored a post for USAID’s Impact Blog on the launch of “Fighting Ebola: A Grand Challenge for Development.” The initiative is designed to provide health care workers on the front lines with better tools to battle Ebola. As part of the program, USAID is rolling out an open innovation platform that will allow the global community to brainstorm, collaborate, and comment on new ideas that generate practical solutions to the Ebola epidemic. The initiative was detailed here.